Drug Maker Simcere Ditches Cell Therapy to Focus on Oncology
Company sells money-losing Simgene unit for $16 million, following recent deals to commercialize two new cancer drugs in China Key Takeaways: New China licensing deals and oncology focus come amid…
Recent Articles
RELATED ARTICLES
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
